Results 21 to 30 of about 53,113 (297)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

Scientific Reports, 2021
FDA-approved anti-PD-L1 antibody drug Atezolizumab is a human IgG1 without glycosylation by an N297A mutation. Aglycosylation of IgG1 has been used to completely remove the unwanted Fc-mediated functions such as antibody-dependent cytotoxicity (ADCC ...
Maohua Li, Rongqing Zhao, Jianxin Chen, Wenzhi Tian, Chenxi Xia, Xudong Liu, Yingzi Li, Song Li, Hunter Sun, Tong Shen, Wenlin Ren, Le Sun   +11 more
doaj   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab

Frontiers in Oncology, 2022
ObjectiveRecently, the significant improvement of atezolizumab and pembrolizumab over chemotherapy for treatment-naïve stage IV non-small cell lung cancer (NSCLC) has been demonstrated, but the cost-effectiveness of these regimens remains unknown ...
Shen Lin, Yiyuan Li, Dian Gu, Shaohong Luo, Xiaoting Huang, Liangliang Dong, Xiongwei Xu, Peili Lin, Xiuhua Weng   +8 more
doaj   +1 more source

Atezolizumab in combination with bevacizumab for the management of patients with hepatocellular cancer in the first-line setting: systematic literature review and meta-analysis

Liver Cancer, 2023
Background & aims: The objective of this systematic literature review (SLR) and network meta-analysis (NMA) is to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line
Arndt Vogel, Richard S. Finn, Marie-Hélène Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, Masatoshi Kudo   +10 more
doaj   +1 more source

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. [PDF]

, 2019
BackgroundNovel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor ...
Bajorin, DF, Bellmunt, J, Choueiri, TK, Climent, MA, Culine, S, de Wit, R, Fong, L, Fradet, Y, Frenkl, TL, Gerritsen, W, Gurney, H, Lee, JL, Nam, K, Necchi, A, Perini, RF, Petrylak, DP, Quinn, DI, Sternberg, CN, Vaughn, DJ, Vogelzang, NJ   +19 more
core   +1 more source

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Journal for ImmunoTherapy of Cancer, 2019
Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients.
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, Sandhya Girish   +12 more
doaj   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer [PDF]

, 2017
Purpose: Two previous single-arm trials have drawn conflicting conclusions regarding the activity of pazopanib in urothelial cancers after failure of platinum-based chemotherapy.
Alexander, Laura, Bahl, Amit, Birtle, Alison, Chakraborti, Prabir, Crabb, Simon J., Dixon-Hughes, Judith, Huddart, Robert A., Hussain, Syed A., Jagdev, Satinder, Jones, Robert J., Kelly, Caroline, Morris, Anna, Paul, James, Powles, Thomas, Protheroe, Andrew S., Stobo, Jon, Stockdale, Andrew, Sundar, Santhanam   +17 more
core   +2 more sources

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources